Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

EntreMed Files to Begin Clinical Trial of Cancer Drug in China

publication date: Jan 7, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
EntreMed, a Washington DC-area biotech, has filed an application with the SFDA to begin clinical trials in China of its cancer treatment, ENMD-2076. The trial is a US-China Phase II test of the drug in patients with triple-negative breast cancer. EntreMed said that adding a China arm to the trial would shorten the time necessary for patient recruitment and save on other costs as well. More details....

Stock Symbol: (NSDQ: ENMD)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners